Pharmaceuticals

Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data

Pharmaceuticals Recent News

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.
Nvidia-Backed Recursion Pharmaceuticals Stock Is Up On Q1 Earnings: Everything You Need To Know
Recursion reported first-quarter revenue of $13.491 million, which beat analyst estimates of $12.65 million, according to Benzinga Pro. The company reported a quarterly loss of 39 cents per share, which beat estimates for a loss of 42 cents per share.
Why Is Nano-Cap Allarity Therapeutics Stock Trading Up On Thursday?
Allarity Therapeutics halts Phase 2 trial, citing compelling early results and plans for regulatory advancement. CEO Thomas Jensen affirms strategic shift. ALLR shares surge 38%.
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at 16,170.36. These are the top stocks that gained the attention of retail traders and investors throughout the day:
GoodRx Holdings Analyst Turns Bullish Ahead Of Q1 Earnings
GoodRx Holdings Inc (NASDAQ: GDRX) got an upgrade last month from Wells Fargo analyst.
EXCLUSIVE: Revolutionary Alzheimer's Drug By IGC Shows Early Success
IGC Pharma's breakthrough Alzheimer's drug, IGC-AD1, shows promising interim results in reducing cognitive and behavioral symptoms, offering hope for patients and families. Its dual-action capability and rapid effectiveness set a new standard in treatment, making it a beacon of hope in the fight against this debilitating disease.
FDA Conditionally Approves Madrigal Pharmaceuticals' Resmetirom As First Treatment For Fatty Liver Disease With Scarring
FDA's accelerated approval for Madrigal Pharmaceuticals' Rezdiffra for noncirrhotic nonalcoholic steatohepatitis with liver scarring. The first treatment for liver scarring due to fatty liver disease. Availability is slated for April in the U.S.
Pfizer/GSK-Backed ViiV Healthcare's HIV Drug Associated With Increased Resistance, WHO Report Says
WHO's latest HIV Drug Resistance Report reveals trends in drug resistance. Discover insights on dolutegravir's impact, challenges in HIVDR monitoring, and recommendations for standardized surveillance.
CASI Pharmaceuticals Blood Cancer Drug Shows Encouraging Clinical Efficacy In Chinese Patients
CASI Pharmaceuticals and BioInvent share promising results for BI-1206 in treating relapsed/refractory indolent Non-Hodgkin's Lymphoma patients in China. Preliminary data reveals clinical efficacy with partial and complete responses, affirming positive safety profiles.
New Legalization Law In Germany Creates Broader Liberties For Pharmacists
The news was trumpeted around the world: Germany, the European Union’s largest economy, surprised the global cannabis industry with the announcement of the legalization of cannabis for restricted recreational use, to be effective April 1.
Pfizer's Mixed Bag: A Look At The Fourth Quarter 2023 Earnings Call - Main Takeaways
Pfizer Inc. (NYSE: PFE) recently held its fourth-quarter earnings call, revealing a year of contrasts for the pharmaceutical giant. While the company faced setbacks, particularly with its COVID-19 products, it also made significant strides in other areas, setting a foundation for future growth.
2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front
On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to charges that resulted from a
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for
Short Seller's Bombshell Report Rattles Grifols: Stock Chart Points To Potential Further Decline
Grifols, the Spanish multinational pharmaceutical titan involved into blood-related medicines, saw its shares fall by 24% on Tuesday.
Healthcare Champions Kick Off 2024
Surprisingly, it is not Big Tech that kicked off 2024 but healtchare champions. Moderna Inc (NASDAQ: MRNA) shares rose after Oppenheimer upgraded the stock due to the Covid-19 vaccine star possibly marketing as many as five products by 2026. Merck & CO Inc (NYSE:
QuantumScape, Peloton, Eli Lilly, Walgreens, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34.
Eli Lilly Launches Website To Help Patients With Home Delivery Options For Weight Loss Medicines
Eli Lilly announced a new website allowing patients to get a weight loss drug prescription through a telehealth provider, with disease management resources, home delivery of medicines.
Apple, Longboard Pharmaceuticals, Coinbase, Moderna, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks experienced mixed results in Tuesday’s trading session. The Dow Jones index showed resilience, gaining around 25 points, a modest rise of 0.07% to 37,715.04. In contrast, the tech-heavy NASDAQ faced a downturn, falling 1.63% to 14,765.94. Similarly, the S&P 500 also witnessed a decline, dropping 0.57% to 4,742.83.
Mark Cuban's Cost Plus Drugs Gets Medication Elon Musk Asked About 6 Months Ago: 'Still Ready To Save Tesla, SpaceX And X a F**kton of Money'
Cuban updated Musk, sharing a link to purchase Ivermectin on Cost Plus Drugs' website.